




# NUTRITION, METABOLISM & CARDIOVASCULAR DISEASES

An international journal on Diabetes, Atherosclerosis and Human Nutrition

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.1</b>
●	<b>Editorial Board</b>	<b>p.1</b>
●	<b>Guide for Authors</b>	<b>p.4</b>



ISSN: 0939-4753

### DESCRIPTION

*Nutrition, Metabolism & Cardiovascular Diseases* is a forum designed to focus on the powerful interplay between **nutritional** and metabolic alterations, and **cardiovascular disorders**. It aims to be a highly qualified tool to help refine strategies against the nutrition-related epidemics of **metabolic** and cardiovascular diseases. By presenting original clinical and experimental findings, it introduces readers and authors into a rapidly developing area of **clinical** and **preventive medicine**, including also **vascular biology**. Of particular concern are the origins, the mechanisms and the means to prevent and control diabetes, atherosclerosis, hypertension, and other nutrition-related diseases.

SID, SISA and SINU members may access the journal contents [here](#)

Electronic usage:

An increasing number of readers access the journal online via ScienceDirect, one of the world's most advanced web delivery systems for scientific, technical and medical information.

### IMPACT FACTOR

2016: 3.679 © Thomson Reuters Journal Citation Reports 2017

### ABSTRACTING AND INDEXING

FSTA (Food Science and Technology Abstracts)  
National Library of Medicine (MEDLARS and MEDLINE)  
PubMed  
ScienceDirect  
EMBASE/Excerpta Medica  
Scopus  
Journal Citation Reports - Science Edition

### EDITORIAL BOARD

*Editor-in-Chief*

**A. Giaccari**, Roma, Italy

### **Co-Editors**

**L. Calabresi**, Milan, Italy  
**F. Galletti**, Naples, Italy  
**A. Siani**, Avellino, Italy (Deputy Editor-in-Chief)  
**P. Strazzullo**, Napoli, Italy (Immediate Past Editor-in-Chief)

### **Associate Editors**

**M. Arca**, Rome, Italy  
**J. Bella**, New York, NY, USA  
**F.P. Cappuccio**, Coventry, UK  
**P. Clifton**, Adelaide, Australia  
**S. Frontoni**, Rome, Italy  
**L. Laviola**, Bari, Italy  
**G. Perseghin**, Monza, Italy  
**A.A. Rivellese**, Naples, Italy  
**A. Rocchini**, Ann Arbor, MI, USA  
**G. L. Russo**, Avellino, Italy  
**G. Schillaci**, Perugia, Italy

### **Editorial Board**

#### **Human Nutrition**

**D. Del Rio**, Università degli Studi di Parma, Parma, Italy  
**R. Giacco**, National Research Council of Italy, Avellino, Italy  
**E. K. Kabagambe**, Nashville, TN, USA  
**V. Krogh**, Milan, Italy  
**B. Lamarche**, Université Laval, Québec, Quebec, Canada  
**D. Molnar**, University of Pécs (Pécsi Tudományegyetem), Pécs, Hungary  
**A. Naska**, Athens, Greece  
**P. Russo**, Avellino, Italy  
**J. Salas-Salvado**, Tarragona, Spain  
**Y. Sanz**, Valencia, Spain  
**L. Scalfi**, University of Naples Federico II, Naples, Italy  
**J. Tur**, Universitat de les Illes Balears, Palma de Mallorca, Spain  
**E. Verduci**, Milan, Italy

#### **Hyperlipidemia and Atherosclerosis**

**F. Angelico**, Sapienza Università di Roma, Rome, Italy  
**M. Averna**, Università degli Studi di Palermo, Palermo, Italy  
**F. Cipollone**, Università degli Studi "G. d'Annunzio" - Chieti-Pescara, Chieti, Italy  
**A. Iannuzzi**, Naples, Italy  
**F. Karpe**, Oxford, UK  
**M. Maranghi**, Rome, Italy  
**L. Masana**, Universitat Rovira i Virgili, Reus, Spain  
**R. Mensink**, Maastricht University, Maastricht, Netherlands  
**G. Norata**, Milan, Italy  
**L. Ose**, Rikshospitalet University Hospital, Oslo, Norway  
**K. Parhofer**, Ludwig-Maximilians-Universität München (LMU), München, Germany  
**A. Pujia**, Università degli studi Magna Graecia di Catanzaro, Catanzaro, Italy  
**Z. Reiner**, Klinicki bolnicki centar Zagreb, Zagreb, Croatia  
**G.B. Vigna**, Ferrara, Italy  
**M. Volpe**, Università di Roma "La Sapienza", Rome, Italy

#### **Diabetes and Metabolism**

**M.A. Abdul-Ghani**, San Antonio, TX, USA  
**D. Accili**, Columbia University, New York, USA  
**G. Annuzzi**, University of Naples Federico II, Naples, Italy  
**R.C. Bonadonna**, Parma, Italy  
**M.F. Brizzi**, University of Turin, Turin, Italy  
**U. Campia**, Washington DC, USA  
**M. Donath**, Universität Basel, Basel, Switzerland  
**G. P. Fadini**, Padua, Italy  
**L. Gnudi**, London, UK  
**M. Hribal**, Catanzaro, Italy  
**S.E. Inzucchi**, New Haven, CT, USA  
**V. Lyssenko**, Malmö, Sweden  
**R.C.W. Ma**, Hong Kong, China

**A. Natali**, Pisa, Italy  
**E.M. Ooi**, Perth, Australia  
**S. Piro**, Catania, Italy  
**S. Prudente**, Rome, Italy  
**G. Reboldi**, Perugia, Italy  
**C.K. Roberts**, Los Angeles, CA, USA  
**A. Solini**, Pisa, Italy  
**M. Uusitupa**, Kuopio, Finland  
**A. Vaag**, Copenhagen, Denmark  
**J. Wilding**, Liverpool, UK  
**F. Zaccardi**, Leicester, UK

#### ***Hypertension/Cardiovascular Diseases***

**P. Barter**, The University of Sydney, Camperdown, New South Wales, Australia  
**L.A. Bazzano**, Tulane University, New Orleans, Louisiana, USA  
**C. Borghi**, Bologna, Italy  
**S. Cocozza**, Università degli studi di Napoli Federico II, Napoli, Italy  
**G.B. Desideri**, L'Aquila, Italy  
**L. Ghiadoni**, Università di Pisa, Pisa, Italy  
**L. Iacoviello**, Catholic University Largo A.Gemelli, Campobasso, Italy  
**V.L. Murthy**, Ann Arbor, MI, USA  
**G. Navis**, University Medical Center Groningen/University of Groningen, Groningen, Netherlands  
**D. Panagiotakos**, Harokopio University, Athens, Greece  
**D. Rendina**, Naples, Italy  
**L. Sechi**, Udine, Italy  
**S. Stranges**, Western University  
**F Veglio**, University of Torino, Torino, Italy  
**K.T. Weber**, University of Tennessee Health Science Center, Memphis, Tennessee, USA  
**A. Zittermann**, Ruhr-University Bochum, Bad Oeynhausen, Germany  
**C Zoccali**, Cnr Ibim Sezione Di Reggio Cal Epidemiologia, Reggio Calabria, Italy

#### ***Statistical Consultants***

**L. D'Elia**, Naples, Italy  
**A. Di Castelnuovo**, Campobasso, Italy

#### ***Emeritus Editors***

**G. Assman**, Munster, German  
**P. Brunetti**, Perugia, Italy  
**M. Mancini**, Naples, Italy  
**G. Riccardi**, Naples, Italy  
**P. Rubba**, Naples, Italy  
**J. Stamler**, Chicago, USA  
**Y. Stein**, Jerusalem, Israel

#### ***Editorial Assistant***

**S. Rotunno**, Università Cattolica del Sacro Cuore, Rome, Italy  
**R. Scala**, Federico II University of Naples, Naples, Italy

## GUIDE FOR AUTHORS

---

### INTRODUCTION

#### *Cover letter, Article types*

Having problems with your submission? Our Editorial Assistants are available to help. Email at: ed.assistant.nmcd@rm.unicatt.it or nmcd@unina.it

### COVER LETTER

Cover letters must state that all authors have seen and approved the study submitted. Provide a statement that no part of the submitted work has been published or is under consideration for publication elsewhere (except in the form of abstract). Provide a statement of financial or other relationships that might lead to a conflict of interest. In the case of clinical trials, provide the registration number and date.

### TYPES OF MANUSCRIPT

**Original Articles** should report original clinical studies or research not previously published or being considered for publication elsewhere. The text should not exceed 3000 words, including list of authors and their affiliations, corresponding author, acknowledgements and figure legends, with an abstract of maximum 250 words, a list of no more than 30 references, and maximum 5 figures/tables (see below for more details on the layout).

**Systematic Reviews** are exhaustive, critical assessments of evidence from different data sources in relation to a given subject in the areas of diagnosis, prevention and treatment of clinical disorders or public health issues relevant to the NMCD readership.

A systematic search of the relevant data sources should be carried out and the items collected should be carefully evaluated for inclusion based on a-priori defined inclusion/exclusion criteria. A description and an analytical graphic representation of the process should be provided. The specific features of the participants' or patients' populations of the studies included in the review should be described as well as the measures of exposure and outcome with the indication of the corresponding data sources. A structured abstract is required (like for Short reviews). The text must not exceed 3000 words including the acknowledgments, with no more than 4 tables and/or figures and maximum 70 references.

**Meta-analyses** should follow the same guidelines as for systematic reviews. They are expected to provide exhaustive information and statistical assessment of pooled estimates of pre-defined outcomes, study heterogeneity and quality, possible publication bias, meta-regression and subgroup analyses when appropriate. Depending on the type of study, Authors are invited to submit PRISMA flow diagrams or MOOSE checklists.

Both systematic reviews and meta-analyses will be dealt with ordinarily as original articles as far as the editorial process is concerned.

**Viewpoints and short review articles, including institutional reviews** of recent developments, are generally upon invitation but authors interested in submitting a proposal are welcome to contact the editors. These articles also undergo peer review. Their length should not exceed 3000 words and should have an abstract of up to 250 words. A limit of 50 references is recommended.

**Letters to the Editor** should be no longer than 500 words and may refer to material previously published in the Journal or report original research findings. These contributions appear in the index of the print copy but are generally published only in the online version of the Journal.

### Guidelines on Clinical Trials Registration

1. NMCD will not consider articles dealing with clinical trials that were not registered before their initiation. The letter accompanying manuscript submission must state trial registration date, number and website where these data can be verified. Submissions that do not comply with these rules will not be admitted to the reviewing process.

2. Registration must be done on a publicly available database, such as [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or any other registry meeting WHO and ICTRP criteria (please refer to <http://www.who.int/ictcp/en/> or <http://www.icmje.org/>).

## Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

### Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## BEFORE YOU BEGIN

### Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding from any company, institution or foundation. All submissions to NMCD need to include a completed ICMJE Conflict of Interest form, which can be downloaded [here](#). If there are no conflicts of interest in relation to the work then this also needs to be indicated on the ICMJE Conflict of Interest form. For [More information](#).

### Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

### Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason

for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

*Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

*Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

The open access fee for this journal is **US\$3000**, excluding taxes. Learn more about [Elsevier's pricing policy](#).

*Green open access*

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### *Referees*

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

## **PREPARATION**

### **Language**

The text should be written in good English (American or British usage is accepted, but not a mixture of these). Please use decimal points (not decimal commas); use a space for thousands (10 000 and above).

### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## **FORMAT**

### *Essential Title page Information*

*Title.* Should be concise (no more than 120 characters), informative and focused on the innovative contents of the study. As titles are often used in information-retrieval systems, abbreviations and formulae are to be avoided.

*Author names and affiliations.* **Provide last name followed by the initial(s) of the first name.** Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. The indication of the individual authors' affiliations must be informative but concise.

*Corresponding author.* Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.**

*Present/permanent address.* If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

*Clinical Trials.* In case of clinical trials, starting July 1st 2009, registration number and date.

*Word counts* for abstract and text, and number of references, figures and tables.

## **Abstract**

An abstract (maximum 250 words) should be typed double spaced on a separate page. The abstract for original articles should be structured under the headings (1) Background and Aims, (2) Methods and Results, (3) Conclusion, (f) registration number for clinical trials. The abstract of review and viewpoint articles should be structured under the headings (1) Aims, (2) Data Synthesis, (3) Conclusions.

### **Text**

The following subheads should be included in all research articles: Introduction, Methods, Results, Discussion, Acknowledgements, References, Appendices, Tables, Figure Legends.

The Methods section should include a statement that the experimental protocols and the process for obtaining informed consent (in human studies) were approved by the appropriate institutional review committee.

For studies on animals, the Methods section should include the species, strain, and supplier/source.

For studies on humans, the Methods section should include a Study Population subheading, under which demographics of study population are defined.

Acronyms should be spelled out in full (in the abstract or text) the first time they are cited. If more than 5 acronyms are used, they should be listed on the title page after the keywords. Avoid jargon.

Measurement units should be reported as standard SI units with traditional units in brackets.

Suppliers of specific instruments or drugs should be given, including the company name and city. All drugs should be referred to by their generic names.

### *Graphical abstract*

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

### *Highlights*

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site.

### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Artwork**



## *Electronic artwork*

### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

### **References**

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/nutrition-metabolism-and-cardiovascular-diseases>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### *Reference style*

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

### *Examples:*

Reference to a journal publication:

[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010;163:51–9.

Reference to a book:

[2] Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*, New York: E-Publishing Inc; 2009, p. 281–304.

Reference to a website:

[4] Cancer Research UK. Cancer statistics reports for the UK, <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>; 2003 [accessed 13.03.03].

Reference to a dataset:

[dataset] [5] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (*J Am Med Assoc* 1997;277:927–34) (see also [Samples of Formatted References](#)).

*Journal abbreviations source*

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

## Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

## Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

## Online Submission

*Nutrition, Metabolism and Cardiovascular Diseases* uses an online submission and review system. Authors can upload their article via our on-line system Elsevier Editorial System at <http://ees.elsevier.com/nmcd>. By accessing the website Authors will be guided stepwise through the uploading of the various files. Editable file formats are necessary. We accept most word-processing formats, but Word, WordPerfect or LaTeX is preferred. Figure files (TIFF, EPS, JPEG) should be uploaded separately. Always keep a backup copy of the electronic file for reference and safety. Save your files using the default extension of the program used. The system generates an Adobe Acrobat PDF version of the article which is used for the reviewing process. Authors, Reviewers and Editors send and receive all correspondence by e-mail and no paper correspondence is necessary. For assistance visit our [Support Center](#).

The instructions also apply to authors of papers appearing in supplements or special issues.

Having problems with your submission? Our Editorial Assistants are available to help. Email at: [ed.assistant.nmcd@rm.unicatt.it](mailto:ed.assistant.nmcd@rm.unicatt.it) or [nmcd@unina.it](mailto:nmcd@unina.it)

## **AFTER ACCEPTANCE**

### **Proofs**

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to [download the free Adobe Reader](#), version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the [Adobe site](#).

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2014 Elsevier | <http://www.elsevier.com>